Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)
Recruiting · NCT06459791 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
Biopsy
What this trial is about
A biopsy of a tumor lesion (breast or other localisation) will be performed for processing to establish avatars (patient-derived organoids -PDO). A personalized tumorogram for each patient will be provided, based on the results of the drug screening (= tumor predicted as sensitive, intermediate, resistant or non-evaluable for each drug tested). Patients with an informative tumorogram will receive one of the recommended treatments (line N+1) in the event of tumor progression, administered according to standard procedures and validated at medical meetings specific to each center, and their fate will be monitored.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patient over 18 years of age
- Advanced breast cancer
- Triple-negative phenotype (HR-/HER2-) or HR+/HER2- after hormone resistance (progression after treatment with hormone therapy + CDK4/6 inhibitor)
- Tumor measurable according to RECISTv1.1 criteria, accessible to biopsy
- Performans Status 0-1
Exclusion criteria
- More than 3 lines of chemotherapy in the advanced setting (excluding hormone therapy/CDK4/6 inhibitor)
- Progressive brain metastases
- Leptomeningeal metastasis
Where it is running
3 locations listed.
- Institut Curie - Paris, France
- Hôpital Saint-Louis - AP-HP Senopole - Paris, France
- Institut Curie - Saint-Cloud, France